This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Spratlin, J. Articles by Mackey, J. R. Search for Related Content PubMed PubMed Citation Articles by Spratlin, J. Articles by Mackey, J. R.

The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas Adenocarcinoma

¹ University of Alberta and ² Cross Cancer Institute, Edmonton, Alberta, Canada; and ³ Centre Hospitalier Lyon Sud, Pierre Benite, France

Purpose: Gemcitabine monotherapy is the standard palliative chemotherapy for pancreatic adenocarcinoma. Gemcitabine requires plasma membrane nucleoside transporter proteins to efficiently enter cells and exert it cytotoxicity. In vitro studies have demonstrated that deficiency of human equilibrative nucleoside transporter 1 (hENT1), the most widely abundant and distributed nucleoside transporter in human cells, confers resistance to gemcitabine toxicity, but the distribution and abundance of nucleoside transporters in normal and malignant pancreatic tissue is unknown.

Experimental Design: We studied tumor blocks from normal pancreas and 21 Alberta patients with gemcitabine-treated pancreatic cancer. Immunohistochemistry on the formalin-fixed, paraffin-embedded tissues was performed with specific hENT1 and human Concentrative Nucleoside Transporter 3 monoclonal antibodies and scored by a pathologist blinded to clinical outcomes.

Results: hENT1 was detected in normal Langerhan cells and lymphocytes but not in normal glandular elements. Patients in whom all adenocarcinoma cells had detectable hENT1 had significantly longer median survivals from gemcitabine initiation than those for whom hENT1 was absent in a proportion (10 to 100%) of adenocarcinoma cells (median survival, 13 versus 4 months, P = 0.01). Immunohistochemistry for human Concentrative Nucleoside Transporter 3 revealed moderate to high-intensity staining in all adenocarcinoma tissue samples.

Conclusions: Patients with pancreatic adenocarcinoma with uniformly detectable hENT1 immunostaining have a significantly longer survival after gemcitabine chemotherapy than tumors without detectable hENT1. Immunohistochemistry for hENT1 shows promise as a molecular predictive assay to appropriately select patients for palliative gemcitabine chemotherapy but requires formal validation in prospective, randomized trials.

This article has been cited by other articles:

				R. Marechal, J. R. Mackey, R. Lai, P. Demetter, M. Peeters, M. Polus, C. E. Cass, J. Young, I. Salmon, J. Deviere, et al. Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma Clin. Cancer Res., April 15, 2009; 15(8): 2913 - 2919. [Abstract] [Full Text] [PDF]

				E. Errasti-Murugarren, M. Molina-Arcas, F. J. Casado, and M. Pastor-Anglada A splice variant of the SLC28A3 gene encodes a novel human concentrative nucleoside transporter-3 (hCNT3) protein localized in the endoplasmic reticulum FASEB J, January 1, 2009; 23(1): 172 - 182. [Abstract] [Full Text] [PDF]

				M. Lopez-Guerra, L. Trigueros-Motos, M. Molina-Arcas, N. Villamor, F. J. Casado, E. Montserrat, E. Campo, D. Colomer, and M. Pastor-Anglada Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells Haematologica, December 1, 2008; 93(12): 1843 - 1851. [Abstract] [Full Text] [PDF]

				R. J. Paproski, A. M. L. Ng, S. Y. M. Yao, K. Graham, J. D. Young, and C. E. Cass The Role of Human Nucleoside Transporters in Uptake of 3'-Deoxy-3'-fluorothymidine Mol. Pharmacol., November 1, 2008; 74(5): 1372 - 1380. [Abstract] [Full Text] [PDF]

				S. A. Veltkamp, D. Pluim, M. A.J. van Eijndhoven, M. J. Bolijn, F. H.G. Ong, R. Govindarajan, J. D. Unadkat, J. H. Beijnen, and J. H.M. Schellens New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine Mol. Cancer Ther., August 1, 2008; 7(8): 2415 - 2425. [Abstract] [Full Text] [PDF]

				D. Santini, G. Perrone, B. Vincenzi, R. Lai, C. Cass, R. Alloni, C. Rabitti, A. Antinori, F. Vecchio, S. Morini, et al. Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer Ann. Onc., April 1, 2008; 19(4): 724 - 728. [Abstract] [Full Text] [PDF]

				B. Laquente, C. Lacasa, M. M. Ginesta, O. Casanovas, A. Figueras, M. Galan, I. G. Ribas, J. R. Germa, G. Capella, and F. Vinals Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model Mol. Cancer Ther., March 1, 2008; 7(3): 638 - 647. [Abstract] [Full Text] [PDF]

				S. A. Veltkamp, J. H. Beijnen, and J. H.M. Schellens Prolonged Versus Standard Gemcitabine Infusion: Translation of Molecular Pharmacology to New Treatment Strategy Oncologist, March 1, 2008; 13(3): 261 - 276. [Abstract] [Full Text] [PDF]

				W. Lam, C.-H. Leung, S. Bussom, and Y.-C. Cheng The Impact of Hypoxic Treatment on the Expression of Phosphoglycerate Kinase and the Cytotoxicity of Troxacitabine and Gemcitabine Mol. Pharmacol., September 1, 2007; 72(3): 536 - 544. [Abstract] [Full Text] [PDF]

				F. Visser, L. Sun, V. Damaraju, T. Tackaberry, Y. Peng, M. J. Robins, S. A. Baldwin, J. D. Young, and C. E. Cass Residues 334 and 338 in Transmembrane Segment 8 of Human Equilibrative Nucleoside Transporter 1 Are Important Determinants of Inhibitor Sensitivity, Protein Folding, and Catalytic Turnover J. Biol. Chem., May 11, 2007; 282(19): 14148 - 14157. [Abstract] [Full Text] [PDF]

				E. Giovannetti, V. Mey, S. Nannizzi, G. Pasqualetti, M. Del Tacca, and R. Danesi Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol. Cancer Ther., June 1, 2006; 5(6): 1387 - 1395. [Abstract] [Full Text] [PDF]

				S. Y. Cho, J. Polster, J. M. Engles, J. Hilton, E. H. Abraham, and R. L. Wahl In Vitro Evaluation of Adenosine 5'-Monophosphate as an Imaging Agent of Tumor Metabolism J. Nucl. Med., May 1, 2006; 47(5): 837 - 845. [Abstract] [Full Text] [PDF]

				V. Sebastiani, F. Ricci, B. Rubio-Viquiera, P. Kulesza, C. J. Yeo, M. Hidalgo, A. Klein, D. Laheru, and C. A. Iacobuzio-Donahue Immunohistochemical and Genetic Evaluation of Deoxycytidine Kinase in Pancreatic Cancer: Relationship to Molecular Mechanisms of Gemcitabine Resistance and Survival Clin. Cancer Res., April 15, 2006; 12(8): 2492 - 2497. [Abstract] [Full Text] [PDF]

				E. Giovannetti, M. Del Tacca, V. Mey, N. Funel, S. Nannizzi, S. Ricci, C. Orlandini, U. Boggi, D. Campani, M. Del Chiaro, et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res., April 1, 2006; 66(7): 3928 - 3935. [Abstract] [Full Text] [PDF]